Characteristics of the earliest cross-neutralizing antibody response to HIV-1.
Recent cross-sectional analyses of HIV-1+ plasmas have indicated that broadly cross-reactive neutralizing antibody responses are developed by 10%-30% of HIV-1+ subjects. The timing of the initial development of such anti-viral responses is unknown. It is also unknown whether the emergence of these responses coincides with the appearance of antibody specificities to a single or multiple regions of the viral envelope glycoprotein (Env). Here we analyzed the cross-neutralizing antibody responses in longitudinal plasmas collected soon after and up to seven years after HIV-1 infection. We find that anti-HIV-1 cross-neutralizing antibody responses first become evident on average at 2.5 years and, in rare cases, as early as 1 year following infection. If cross-neutralizing antibody responses do not develop during the first 2-3 years of infection, they most likely will not do so subsequently. Our results indicate a potential link between the development of cross-neutralizing antibody responses and specific activation markers on T cells, and with plasma viremia levels. The earliest cross-neutralizing antibody response targets a limited number of Env regions, primarily the CD4-binding site and epitopes that are not present on monomeric Env, but on the virion-associated trimeric Env form. In contrast, the neutralizing activities of plasmas from subjects that did not develop cross-neutralizing antibody responses target epitopes on monomeric gp120 other than the CD4-BS. Our study provides information that is not only relevant to better understanding the interaction of the human immune system with HIV but may guide the development of effective immunization protocols. Since antibodies to complex epitopes that are present on the virion-associated envelope spike appear to be key components of earliest cross-neutralizing activities of HIV-1+ plasmas, then emphasis should be made to elicit similar antibodies by vaccination.
Seattle BioMed, Seattle, Washington, USA.
Iliyana
I
Mikell
D Noah
DN
Sather
Spyros A
SA
Kalams
Marcus
M
Altfeld
Galit
G
Alter
Leonidas
L
Stamatatos
D003429:Cross Reactions; D015483:HIV Antibodies / Q000097:blood* / Q000276:immunology; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D054884:Host-Pathogen Interactions / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests
D015483:HIV Antibodies
J Virol. 2005 Jan;79(2):1252-61
15613352
Nature. 2009 Apr 2;458(7238):636-40
19287373
J Virol. 2001 Nov;75(22):10892-905
11602729
J Virol. 2009 Jan;83(2):1045-59
19004942
J Virol. 2007 Apr;81(8):4033-43
17287272
PLoS Pathog. 2010 Aug 05;6(8):e1001028
20700449
J Immunol. 1993 Jan 15;150(2):635-43
7678279
J Virol. 2007 May;81(10):5413-7
17329337
Nat Immunol. 2010 Jun;11(6):535-42
20453843
J Virol. 2005 Apr;79(8):5232-7
15795308
Immunity. 2008 Jul 18;29(1):138-49
18599325
Virology. 2008 Jul 20;377(1):170-83
18499210
J Virol. 2007 Jun;81(12):6548-62
17409160
J Virol. 1996 Feb;70(2):1100-8
8551569
J Virol. 2009 Nov;83(21):11265-74
19692477
J Virol. 2006 Dec;80(23):11776-90
16971434
Virology. 2007 Sep 30;366(2):433-45
17560621
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14759-64
16203977
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
12644702
J Virol. 2009 Apr;83(8):3617-25
19193787
Int Immunol. 1997 Sep;9(9):1281-90
9310831
J Virol. 2007 Feb;81(3):1350-9
17079307
J Exp Med. 2010 Aug 30;207(9):1995-2002
20679402
Virology. 2010 Jan 20;396(2):339-48
19922969
J Virol. 2008 Dec;82(24):12449-63
18842730
J Virol. 2009 Jul;83(14):7337-48
19439467
Nat Med. 2007 Sep;13(9):1032-4
17721546
Blood. 2004 Aug 15;104(4):942-7
15117761
Virology. 2008 Mar 15;372(2):442-56
18068750
J Virol. 2009 Jan;83(2):757-69
18987148
AIDS. 2007 Mar 30;21(6):693-702
17413690
J Virol. 2002 Jul;76(14):7293-305
12072528
J Virol. 2004 Dec;78(23):13232-52
15542675
J Virol. 2002 Jul;76(14):7306-21
12072529
J Infect Dis. 2010 Apr 1;201(7):1045-53
20170371
J Virol. 2009 Oct;83(19):10269-74
19640996
Science. 2009 Oct 9;326(5950):285-9
19729618
J Virol. 2006 Jun;80(11):5211-8
16699001
J Virol. 2008 Feb;82(4):1860-9
18057243
Vaccine. 2010 May 26;28 Suppl 2:B8-12
20510750
AIDS Res Hum Retroviruses. 2002 May 20;18(8):567-76
12036486
AIDS. 2009 Nov 27;23(18):2405-14
19770692
J Virol. 1994 Aug;68(8):5142-55
8035514
Nat Med. 2009 Aug;15(8):866-70
19525964
PLoS One. 2010 Jan 20;5(1):e8805
20098712
J Virol. 2005 Aug;79(16):10108-25
16051804
J Virol. 2006 Sep;80(17):8745-62
16912322
J Virol. 2010 Apr;84(7):3443-53
20106929
J Virol. 2007 Jun;81(12):6187-96
17409164
J Virol. 2010 May;84(10):5032-42
20219932
J Virol. 2010 Oct;84(20):10510-21
20686044
J Virol. 2006 Jun;80(12):6155-64
16731954
J Immunol. 2004 Jul 1;173(1):68-78
15210760
J Virol. 2010 Feb;84(3):1631-6
19923174
AIDS Res Hum Retroviruses. 1996 Jul 1;12(10):911-24
8798976
J Mol Biol. 2009 Jun 5;389(2):365-75
19376130
Science. 2009 Nov 20;326(5956):1123-7
19965434
J Virol. 2006 Oct;80(19):9586-98
16973562
J Virol. 2009 Jan;83(1):188-99
18922865
J Virol. 2008 Dec;82(23):11651-68
18815292
J Virol. 2003 Jan;77(2):1084-91
12502824